The effect of antenatal steroids on metabolic bone disease of prematurity
-
Sara Erol
,
Mustafa Senol Akin
Abstract
Objectives
The study aimed to evaluate the impact of antenatal steroid administration, a key intervention for reducing early mortality and morbidity in preterm infants, on the development of metabolic bone disease.
Methods
This single-center retrospective study was conducted in a Level III neonatal intensive care unit from October 2020 to December 2023.
Results
It included 173 infants born before 32 weeks of gestation, with a mean birth weight of 1,338 ± 293 g. Metabolic bone disease, diagnosed at four weeks of age based on serum phosphorus and alkaline phosphatase levels, was identified in 26 (15 %) of the infants. Regression analysis examined prenatal factors, including birth weight, intrauterine growth restriction, respiratory distress syndrome, gender, and antenatal steroid exposure, revealing that only lower birth weight was an independent risk factor for metabolic bone disease.
Conclusions
Antenatal steroid administration did not significantly influence the diagnosis of metabolic bone disease when assessed using biochemical markers at four weeks of age. These findings underscore the importance of birth weight in the risk profile for metabolic bone disease while indicating that antenatal steroids are not a contributing factor.
-
Research ethics: Ethical approval for this study was granted by the local Institutional Review Board (Approval ID: [E2-23-4569], Date: [19.07.2023]) and the study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).
-
Informed consent: Applicable.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Use of Large Language Models, AI and Machine Learning Tools: None declared.
-
Conflict of interest: The authors state no conflict of interest.
-
Research funding: None declared.
-
Data availability: Data available on request due to privacy/ethical/legal restrictions.
References
1. McGoldrick, E, Stewart, F, Parker, R, Dalziel, SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2020;12:CD004454. https://doi.org/10.1002/14651858.CD004454.pub4.Search in Google Scholar PubMed PubMed Central
2. Jobe, AH, Goldenberg, RL, Kemp, MW. Antenatal corticosteroids: an updated assessment of anticipated benefits and potential risks. Am J Obstet Gynecol 2024;230:330–9. https://doi.org/10.1016/j.ajog.2023.09.013.Search in Google Scholar PubMed
3. Kemp, MW, Schmidt, AF, Jobe, AH. Optimizing antenatal corticosteroid therapy. Semin Fetal Neonatal Med 2019;24:176–81. https://doi.org/10.1016/j.siny.2019.05.003.Search in Google Scholar PubMed
4. Committee on Obstetric Practice. Committee Opinion No. 713: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2017;130:e102–9. https://doi.org/10.1097/AOG.0000000000002237.Search in Google Scholar PubMed
5. WHO recommendations on antenatal corticosteroids for improving preterm birth outcomes. Geneva: World Health Organization; 2022.Search in Google Scholar
6. Rodriguez, A, Wang, Y, Ali Khan, A, Cartwright, R, Gissler, M, Järvelin, MR. Antenatal corticosteroid therapy (ACT) and size at birth: a population-based analysis using the Finnish Medical Birth Register. PLoS Med 2019;16:e1002746. https://doi.org/10.1371/journal.pmed.1002746.Search in Google Scholar PubMed PubMed Central
7. Tao, S, Du, J, Chi, X, Zhu, Y, Wang, X, Meng, Q, et al.. China National Birth Cohort (CNBC Study Group). Associations between antenatal corticosteroid exposure and neurodevelopment in infants. Am J Obstet Gynecol 2022;227:759.e1–759.e15. https://doi.org/10.1016/j.ajog.2022.05.060.Search in Google Scholar PubMed
8. Fonseca, L, Ramin, SM, Mele, L, Wapner, RJ, Johnson, F, Peaceman, AM, et al.. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal Fetal Medicine Units Network (MFMU). Bone metabolism in fetuses of pregnant women exposed to single and multiple courses of corticosteroids. Obstet Gynecol 2009;114:38–44. https://doi.org/10.1097/AOG.0b013e3181a82b85.Search in Google Scholar PubMed PubMed Central
9. Backström, MC, Kuusela, AL, Mäki, R. Metabolic bone disease of prematurity. Ann Med 1996;28:275–82. https://doi.org/10.3109/07853899608999080.Search in Google Scholar PubMed
10. Perrone, S, Caporilli, C, Grassi, F, Ferrocino, M, Biagi, E, Dell’Orto, V, et al.. Prenatal and neonatal bone health: updated Review on early identification of newborns at high risk for osteopenia. Nutrients 2023;15:3515. https://doi.org/10.3390/nu15163515.Search in Google Scholar PubMed PubMed Central
11. Rayannavar, A, Calabria, AC. Screening for metabolic bone disease of prematurity. Semin Fetal Neonat Med 2020;25:101086. https://doi.org/10.1016/j.siny.2020.101086.Search in Google Scholar PubMed
12. Abdallah, EAA, Said, RN, Mosallam, DS, Moawad, EMI, Kamal, NM, Fathallah, MGE. Serial serum alkaline phosphatase as an early biomarker for osteopenia of prematurity. Medicine (Baltimore) 2016;95:e4837. https://doi.org/10.1097/MD.0000000000004837.Search in Google Scholar PubMed PubMed Central
13. Backström, MC, Kouri, T, Kuusela, AL, Sievänen, H, Koivisto, AM, Ikonen, RS, et al.. Bone isoenzyme of serum alkaline phosphatase and serum inorganic phosphate in metabolic bone disease of prematurity. Acta Paediatr 2000;89:867–73. https://doi.org/10.1111/j.1651-2227.2000.tb00395.x.Search in Google Scholar
14. Lawson, EE. Antenatal corticosteroids-too much of a good thing? JAMA 2001;286:1628–30. https://doi.org/10.1001/jama.286.13.1628.Search in Google Scholar PubMed
15. Ali, RS, Al-Sudani, H, Tan, IJ. Osteonecrosis of bilateral distal femurs in a pregnant patient following antenatal betamethasone. Cureus 2022;14:e22735. https://doi.org/10.7759/cureus.22735.Search in Google Scholar PubMed PubMed Central
16. Razaz, N, Skoll, A, Fahey, J, Allen, VM, Joseph, KS. Trends in optimal, suboptimal, and questionably appropriate receipt of antenatal corticosteroid prophylaxis. Obstet Gynecol 2015;125:288–96. https://doi.org/10.1097/AOG.0000000000000629.Search in Google Scholar PubMed
17. Rizzo, G, Mappa, I, Bitsadze, V, Khizroeva, J, Makatsariya, A, D’Antonio, F. Administration of antenatal corticosteroid is associated with reduced fetal growth velocity: a longitudinal study. J Matern Fetal Neonatal Med 2022;35:2775–80. https://doi.org/10.1080/14767058.2020.1800634.Search in Google Scholar PubMed
18. French, NP, Hagan, R, Evans, SF, Godfrey, M, Newnham, JP. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol 1999;180:114–21. https://doi.org/10.1016/s0002-9378(99)70160-2.Search in Google Scholar PubMed
19. Abrantes, MA, Valencia, AM, Bany-Mohammed, F, Aranda, JV, Beharry, KD. Intergenerational influence of antenatal betamethasone on growth, growth factors, and neurological outcomes in rats. Reprod Sci 2020;27:418–31. https://doi.org/10.1007/s43032-019-00073-w.Search in Google Scholar PubMed
20. Su, J, Chai, Y, Ji, Z, Xie, Y, Yu, B, Zhang, X. Cellular senescence mediates the detrimental effect of prenatal dexamethasone exposure on postnatal long bone growth in mouse offspring. Stem Cell Res Ther 2020;11:270. https://doi.org/10.1186/s13287-020-01790-9.Search in Google Scholar PubMed PubMed Central
21. Chou, FS, Clark, RH, Yeh, HW. The association between antenatal corticosteroids exposure and postnatal growth in infants born between 23 and 29 weeks of gestation. J Perinatol 2024;44:561–7. https://doi.org/10.1038/s41372-024-01871-0.Search in Google Scholar PubMed
22. McKinlay, CJD, Cutfield, WS, Battin, MR, Dalziel, SR, Crowther, CA, Harding, JE, ACTORDS Follow-up Group. Mid-childhood bone mass after exposure to repeat doses of antenatal Glucocorticoids: a randomized trial. Pediatrics 2017;139:e20164250. https://doi.org/10.1542/peds.2016-4250.Search in Google Scholar PubMed
23. Chacham, S, Pasi, R, Chegondi, M, Ahmad, N, Mohanty, SB. Metabolic bone disease in premature neonates: an unmet challenge. J Clin Res Pediatr Endocrinol 2020;12:332–9. https://doi.org/10.4274/jcrpe.galenos.2019.2019.0091.Search in Google Scholar PubMed PubMed Central
24. Travers, CP, Clark, RH, Spitzer, AR, Das, A, Garite, TJ, Carlo, WA. Exposure to any antenatal corticosteroids and outcomes in preterm infants by gestational age: prospective cohort study. BMJ 2017;356:j1039. https://doi.org/10.1136/bmj.j1039.Search in Google Scholar PubMed PubMed Central
© 2025 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Review
- A recent update on childhood obesity: aetiology, treatment and complications
- Original Articles
- Chronotype, sleep, and glycemic control in children and adolescents with type 1 diabetes: a case-control study
- Determinants of childhood and adolescent obesity and it’s effect on metabolism in South Indian population
- Evaluation of continuous glucose monitoring and nutritional status in glycogen storage diseases
- Retrospective assessment of hepatic involvement in patients with inherited metabolic disorders: nine-year single-center experience
- Relationships among biological sex, body composition, and bone mineral density in young persons with and without diabetes
- The clinical characteristics of 10 cases and adult height of six cases of rare familial male-limited precocious puberty
- Optimal timing of repeat thyroid fine-needle aspiration biopsy
- Medium-chain acyl-CoA dehydrogenase deficiency in North Macedonia – ten years experience
- The effect of antenatal steroids on metabolic bone disease of prematurity
- Prader-Willi syndrome gene expression profiling of obese and non-obese patients reveals transcriptional changes in CLEC4D and ANXA3
- Early-onset growth hormone treatment in Prader–Willi syndrome attenuates transition to severe obesity
- Case Reports
- Neonatal severe hyperparathyroidism with inactivating calcium sensing receptor (CaSR) mutation (p.I81K)
- Clinical manifestations and molecular genetics of seven patients with Niemann–Pick type-C: a case series with a novel variant
- Expanding the genotypic spectrum of 3β-hydroxy-δ5-C27-steroid dehydrogenase (HSD3B7) deficiency: novel mutations and clinical outcomes
Articles in the same Issue
- Frontmatter
- Review
- A recent update on childhood obesity: aetiology, treatment and complications
- Original Articles
- Chronotype, sleep, and glycemic control in children and adolescents with type 1 diabetes: a case-control study
- Determinants of childhood and adolescent obesity and it’s effect on metabolism in South Indian population
- Evaluation of continuous glucose monitoring and nutritional status in glycogen storage diseases
- Retrospective assessment of hepatic involvement in patients with inherited metabolic disorders: nine-year single-center experience
- Relationships among biological sex, body composition, and bone mineral density in young persons with and without diabetes
- The clinical characteristics of 10 cases and adult height of six cases of rare familial male-limited precocious puberty
- Optimal timing of repeat thyroid fine-needle aspiration biopsy
- Medium-chain acyl-CoA dehydrogenase deficiency in North Macedonia – ten years experience
- The effect of antenatal steroids on metabolic bone disease of prematurity
- Prader-Willi syndrome gene expression profiling of obese and non-obese patients reveals transcriptional changes in CLEC4D and ANXA3
- Early-onset growth hormone treatment in Prader–Willi syndrome attenuates transition to severe obesity
- Case Reports
- Neonatal severe hyperparathyroidism with inactivating calcium sensing receptor (CaSR) mutation (p.I81K)
- Clinical manifestations and molecular genetics of seven patients with Niemann–Pick type-C: a case series with a novel variant
- Expanding the genotypic spectrum of 3β-hydroxy-δ5-C27-steroid dehydrogenase (HSD3B7) deficiency: novel mutations and clinical outcomes
